Single-center, prospective, and observational study on the management and treatment of impetigo in a pediatric population.

Abstract

OBJECTIVE:

Ozenoxacin is a new antibiotic used to treat non-bullous impetigo. The aim of this study is to evaluate the microbiological and clinical efficacy of topical ozenoxacin 1% cream after 5-day twice-daily treatment, in pediatric patients with impetigo.

PATIENTS AND METHODS:

This observational and prospective study included patients aged 6 months to 18 years, with non-bullous impetigo. Efficacy was measured using the Skin Infection Rating Scale (SIRS) and microbiological culture at the first visit (T0), at the second visit after 72 hours (T1) and after 5 days (T2). Safety and tolerability were also evaluated.

RESULTS:

A total of 50 patients was enrolled. A reduction of SIRS score >10% after 72 hours of treatment was noticed in all patients, while a complete reduction was assessed after 5 days in all the population. Microbiologic success rates for ozenoxacin at T1 was 92% (four patients had original pathogens in the specimen culture from the skin area), whereas at T2, it was 100%.

CONCLUSIONS:

Topical ozenoxacin has strong efficacy in treating impetigo in pediatric patients. Ozenoxacin's clinical and microbiological rapid onset of response led to consider this antibiotic a novel efficacy option for the treatment of impetigo.

• Authors: A Gatto, L Capossela, S Ferretti, L Di Sarno, A Oliveti, D Talamonti, A Curatola, A Chiaretti, B Fiori
• Journal: European review for medical and pharmacological sciences (Eur Rev Med Pharmacol Sci) Vol. 27 Issue 19 Pg. 9273-9278 (Oct 2023) ISSN: 2284-0729 [Electronic] Italy
• PMID: 37843341 (Publication Type: Observational Study, Journal Article)

Chemical References

• ozenoxacin
• Anti-Bacterial Agents

Topics

• Humans
• Child
• Impetigo (diagnosis, drug therapy, microbiology)
• Prospective Studies
• Anti-Bacterial Agents
• Systemic Inflammatory Response Syndrome